A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells - ND
- Conditions
- advanced breast carcerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastatic
- Registration Number
- EUCTR2007-002155-17-IT
- Lead Sponsor
- GlaxoSmithKline Research & Development Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- 62
1. Signed written informed consent 2. Female patients, age ≥ 18 years 3. Histologically confirmed diagnosis of HER-2 negative (i.e. no gene amplification by FISH or IHC 2+ and no amplification by FISH or IHC 0/1+) infiltrating primary breast cancer. UK centres will additionally require patients with EGFR positive primary breast cancer (i.e., IHC 3+ or FISH) 4. Evidence of HER-2 or EGFR positive circulating tumour cells (≥50% CTCs or FISH positive) in a peripheral blood sample taken at screening visit. 5. Metastatic disease with at least one measurable lesion as per RECIST criteria classification [Therasse, 2000] 6. No brain metastasis requiring local therapy. Stable or asymptomatic subjects are allowed. 7. Availability of tumour block or at least six unstained 4 µ sections of the primary tumour to be sent to the central lab after eligibility confirmation for HER-2 central testing by FISH. 8. Eastern Cooperative Oncology Group (ECOG) score for performance status 0 to 2 (Appendix 1) 9. Life expectancy > 12 weeks 10. Adequate baseline organ function at screening visit: Hematologic function: ANC ≥ 1,000 / mm3, PLT ≥ 50,000 / mm3 , Hb ≥ 9g / dL (after transfusion if needed) Hepatic function: GOT/GPT/alkaline phosphatase ≤ 3 N without liver metastases or ≤ 5 N if documented liver metastases; total bilirubin: ≤1.5 N unless due to Gilbert?s syndrome Renal function: serum creatinine ≤ 2.0mg/dL or Calculated Creatinine (Appendix 2) Clearance ≥ 25mL/min 11. Normal left ventricular ejection fraction (LVEF) by echocardiogram or MUGA. 12. Negative serum pregnancy test (only in childbearing potential female) 13. Patients with reproductive potential needs consistent and correct use of adequate non-hormonal methods of birth control (barrier methods or intrauterine device) 14. Previous treatment with anthracyclines and/or taxanes in the neo-adjuvant, adjuvant or advanced setting
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. Any unstable systemic disease including active infections, significant cardiovascular disease, as well as myocardial infarction within the previous year, any significant hepatic, renal or metabolic disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of study medication or that might affect the interpretation of the results or render the patient at high risk from treatment complications. 2. Pregnant or lactating women 3. Dementia, altered mental status, or any psychiatric condition that could prohibit the understanding or rendering of informed consent 4. Lack of physical integrity of the upper gastrointestinal (GI) tract, poor absorption of the GI tract or inability to take oral medication 5. Other co-existing malignancy or malignancies within the last 5 years with the exception of basal cell carcinoma or in-situ carcinoma 6. Concurrent anti-cancer therapies (chemo or hormonal therapy) other than study drug 7. Concurrent treatment with an investigational agent or participation in any investigational drug study within 4 weeks preceding treatment start 8. Concurrent radiotherapy to the only target lesion or concurrent bisphosphonates if bone metastases are the only target lesions 9. Previous treatment with anti HER-2 or anti-EGFR therapies 10. Protocol specified treatment regimens that would be inappropriate for the management of the subject
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method